Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation, has made a new investment in SeraGene Therapeutics, a biotechnology company developing RNA-based and nanomedicine treatments for blood coagulation disorders. The financing adds a mission-driven investor to SeraGene’s growing roster of backers as the company advances therapies designed to improve outcomes for patients with inherited bleeding conditions.
SeraGene was founded as a spinout of the Versiti Blood Research Institute in Wisconsin and the Center for Blood Research at the University of British Columbia, with support from Canada’s Nanomedicines Innovation Network. Headquartered in Vancouver, the company has rapidly gained recognition for its innovation in RNA technologies. It earned a Company to Watch designation at the Life Sciences BC Awards, won the Coup de Coeur prize at Sweet Pharma Day, and was named a 2025 Eli Lilly Grand Challenge finalist.
The company is developing proprietary RNA therapeutics that either suppress plasminogen to stabilize clots or increase the expression of key coagulation-related genes. These therapies are delivered using advanced lipid nanoparticles that precisely target liver cells. This approach is designed to enhance treatment accuracy and reduce dosing burdens when compared with traditional therapeutic options. SeraGene aims to restore healthy blood function and improve the quality of life for patients, including women and individuals with rare coagulation disorders who frequently face diagnostic and treatment gaps.
Pathway to Cures’ investment adds to the list of early supporters, including Hextwo Capital, as well as funders such as Adage Capital Partners, Blue Owl Healthcare Opportunities, Boxer Capital, Commodore Capital, Deep Track Capital, Foresite Capital, and Logos Capital. The venture philanthropy fund aims to accelerate innovation in bleeding disorders and women’s health, and its reinvestment model is designed to amplify long-term impact across inheritable blood conditions.
KEY QUOTES
“The potential for SeraGene’s innovative therapies to improve lives in our bleeding disorders community, especially for women and girls, makes this an exciting partnership for us. We are delighted to expand our portfolio with this strategic investment and impact the treatment of bleeding disorders including von Willebrand disease (VMD) with a focus on women’s health.”
Teri Willey, Managing Director and Officer, Pathway to Cures Venture Fund
